Dr Rajneesh Kumar, a senior consultant at the Department of Gastroenterology and Hepatology, Singapore General Hospital, highlights the high prevalence of hepatitis, and speaks to Roshini Claire Anthony about the transmission, prevention, and treatment of the disease.
Dr Dariusz P. Olszyna, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the importance of early detection to prevent the spread and complications related to sexually-transmitted infections (STIs).
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Non-alcoholic fatty liver disease (NAFLD) – a clinicopathological spectrum comprising hepatic steatosis or non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) – is the hepatic manifestation of metabolic syndrome recognized as a leading cause of liver morbidity and mortality. Dr Loo Wai Mun, Consultant at the Division of Gastroenterology and Hepatology, National University Hospital, Singapore, speaks with Audrey Abella to discuss how NAFLD can be best managed in primary care.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Hepatology - Malaysia digital copy today!
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).